<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04620473</url>
  </required_header>
  <id_info>
    <org_study_id>MISC-Anlotinib+Capeox</org_study_id>
    <nct_id>NCT04620473</nct_id>
  </id_info>
  <brief_title>Anlotinib Hydrochloride Combined With Capeox in the Neoadjuvant Treatment of Locally Advanced Rectal Cancer</brief_title>
  <official_title>Anlotinib Hydrochloride Combined With Capeox in the Neoadjuvant Treatment of Locally Advanced Rectal cancer-a Prospective, Open, Single Center and Randomized Controlled Phase Ⅱ Clinical Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Shanghai Minimally Invasive Surgery Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Shanghai Minimally Invasive Surgery Center</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      Prospectively Investigate the effectiveness and safety of anlotinib hydrochloride combined&#xD;
      with Capeox in neoadjuvant treatment of patients with locally advanced rectal cancer.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Withdrawn</overall_status>
  <why_stopped>
    No approval from ethical committee&#xD;
  </why_stopped>
  <start_date type="Anticipated">November 1, 2023</start_date>
  <completion_date type="Anticipated">October 1, 2024</completion_date>
  <primary_completion_date type="Anticipated">December 1, 2023</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Objective Response Rate（ORR）</measure>
    <time_frame>an average of three months</time_frame>
    <description>Refers to the proportion of subjects whose tumors have shrunk to a certain amount and maintained for a certain period of time in the FAS concentration, including CR and PR cases</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Pathological complete response rate</measure>
    <time_frame>one month after surgery</time_frame>
    <description>Refers to the pathological examination of primary tumors and lymph node surgical specimens without residual infiltrating tumor cells (ypT0N0)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>R0 resection rate</measure>
    <time_frame>one month after surgery</time_frame>
    <description>Refers to the surgically removed tissue without residual cancer cells</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Local disease recurrence time</measure>
    <time_frame>3 years after surgery</time_frame>
    <description>Refers to the tumor reappearing at or near the same site as the primary cancer. The starting time is the first day after surgery.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall survive</measure>
    <time_frame>3 years after surgery</time_frame>
    <description>Refers to the time from the start of randomization to death due to any cause. The starting time is the first day after surgery.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Disease-free survival rate</measure>
    <time_frame>3 years after surgery</time_frame>
    <description>It refers to the time from the beginning of randomization to the incurable resection, local recurrence or metastasis, or death from any cause. The starting time is the first day after surgery.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Postoperative complications</measure>
    <time_frame>one month after surgery</time_frame>
    <description>Postoperative complications</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">0</enrollment>
  <condition>Neoadjuvant Treatment</condition>
  <condition>Rectal Cancer</condition>
  <condition>Anlotinib</condition>
  <arm_group>
    <arm_group_label>Anlotinib+Capeox</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>neoadjuvant treatment with Anlotinib hydrochloride combined with Capeox</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Capeox</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>neoadjuvant treatment with Capeox</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Anlotinib+Capeox</intervention_name>
    <description>to use Anlotinib hydrochloride combined with Capeox in the neoadjuvant treatment of locally advanced rectal cancer</description>
    <arm_group_label>Anlotinib+Capeox</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Capeox</intervention_name>
    <description>to use Capeox in the neoadjuvant treatment of locally advanced rectal cancer</description>
    <arm_group_label>Capeox</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Subjects voluntarily join the study and sign an informed consent form, have good&#xD;
             compliance and cooperate with follow-up;&#xD;
&#xD;
          2. Male or female patients between the ages of 18-75;&#xD;
&#xD;
          3. Patients diagnosed as rectal adenocarcinoma by histology or cytology;&#xD;
&#xD;
          4. Stage: Locally advanced stage (T3-4N0M0 or T1-4N+M0);&#xD;
&#xD;
          5. Evaluation of middle and low rectal cancer with the lower pole of the tumor less than&#xD;
             12 cm from the anal margin by MRI;&#xD;
&#xD;
          6. Have not received other anti-angiogenic drugs or chemotherapy drugs in the past;&#xD;
&#xD;
          7. ECOG (Eastern US Cooperative Oncology Group) score: 0-1 points;&#xD;
&#xD;
          8. Has sufficient organ and bone marrow function&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Other malignant tumors that have appeared or are currently suffering from within 5&#xD;
             years, except for cured cervical carcinoma in situ, non-melanoma skin cancer and&#xD;
             superficial bladder tumors [Ta (non-invasive tumor), Tis (carcinoma in situ) ) And T1&#xD;
             (tumor infiltration basement membrane)];&#xD;
&#xD;
          2. A distant transfer occurs;&#xD;
&#xD;
          3. Those who have multiple factors that affect oral medications (such as inability to&#xD;
             swallow, chronic diarrhea, etc.);&#xD;
&#xD;
          4. Accompanied by pleural effusion or ascites, causing respiratory syndrome (NCI-CTC AE&#xD;
             V5.0 grade ≥ 2 dyspnea);&#xD;
&#xD;
          5. Patients with any severe and/or uncontrollable disease；&#xD;
&#xD;
          6. Patients with gastrointestinal diseases with bleeding tendency (such as active&#xD;
             gastrointestinal ulcers) or patients determined by the researcher to cause&#xD;
             gastrointestinal bleeding, perforation or obstruction&#xD;
&#xD;
          7. Patients whose imaging shows that the tumor has invaded the tissues around important&#xD;
             blood vessels or the investigator judges that the tumor is likely to invade important&#xD;
             blood vessels and cause fatal bleeding during the follow-up study;&#xD;
&#xD;
          8. Received major surgical treatment, open biopsy or obvious traumatic injury within 28&#xD;
             days before grouping;&#xD;
&#xD;
          9. Regardless of the severity, patients with any signs of bleeding or medical history;&#xD;
             within 4 weeks before grouping, patients with any bleeding or bleeding events NCI-CTC&#xD;
             AE V5.0 grade ≥ 3, unhealed wounds, ulcers Or fracture&#xD;
&#xD;
         10. Those who have had arterial/venous thrombotic events within 6 months, such as&#xD;
             cerebrovascular accidents (including temporary ischemic attacks), deep vein thrombosis&#xD;
             and pulmonary embolism;&#xD;
&#xD;
         11. People with a history of psychotropic drug abuse and unable to quit or have mental&#xD;
             disorders;&#xD;
&#xD;
         12. Participated in other anti-tumor drug clinical trials within four weeks;&#xD;
&#xD;
         13. According to the judgment of the investigator, those with concomitant diseases that&#xD;
             seriously endanger the safety of the patient or affect the completion of the study;&#xD;
&#xD;
         14. Female patients who are pregnant or breastfeeding;&#xD;
&#xD;
         15. Known hypersensitivity to any study drug.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <verification_date>September 2021</verification_date>
  <study_first_submitted>October 29, 2020</study_first_submitted>
  <study_first_submitted_qc>November 6, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">November 9, 2020</study_first_posted>
  <last_update_submitted>September 22, 2021</last_update_submitted>
  <last_update_submitted_qc>September 22, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">September 28, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Shanghai Minimally Invasive Surgery Center</investigator_affiliation>
    <investigator_full_name>Cai Zhenghao</investigator_full_name>
    <investigator_title>Attending surgeon of gastrointestinal surgery, Ruijin Hospital, Shanghai Jiaotong University School of Medicine</investigator_title>
  </responsible_party>
  <keyword>Neoadjuvant Treatment</keyword>
  <keyword>Rectal cancer</keyword>
  <keyword>Anlotinib</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Rectal Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Oxaliplatin</mesh_term>
    <mesh_term>Capecitabine</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

